PD-1 and TIM3 blockade, either alone or in combination with conventional AML therapies like hypomethylating agents, has shown some signal in early clinical trials, but none have examined NK phenotypes or function as clinical correlates, and none combined checkpoint blockade with NK adoptive therapies (116). This evidence concerns the gene HAVCR2 and acute myeloid leukemia.